Lemborexant (DAYVIGO), approved by FDA in December 2019, used in the treatment of adult patients with insomnia. It is an orexin receptor antagonist. Part of this molecule contains a cyclopropyl cycle. We have created a set of in-stock Building Blocks, which contains this cycle, to generate new ideas for your projects.